Slenyto

®

Sleep more. Rest more.

Achieve more.

 

Why Slenyto®?

Slenyto® is the first and only pharmacotherapy that is approved for the treatment of insomnia in children with Autism Spectrum Disorder (ASD) and/or Smith-Magenis Syndrome (SMS). Slenyto® is a prolonged-release melatonin minitablet developed specifically for the treatment of insomnia in these children, addressing their specific needs. 

Slenyto symbol
Slenyto package
Slenyto is easy to manage
Easy to Manage​
  • Just 3mm diameter

  • Dose adjustable

  • Favourable safety 

Slenyto signficantly improves sleep
Proven Clinical Evidence
  • Improves Total Sleep Time

  • Shortens Sleep Latency

  • Increases Longest Sleep Duration

 
 
Slenyto presenter

Insomnia & ASD

50-80% of children with ASD suffer from insomnia, much more than normally developed children.  

Sleep deficit exacerbates cognitive and behavioural problems in ASD children and adolescent, and is also challenging for their families.